{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:11:33Z","timestamp":1780449093019,"version":"3.54.1"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for a significant proportion of all cancer cases in Korea. This case report presents a unique instance of spontaneous dramatic tumor regression in a 42-year-old Korean male diagnosed with clear cell RCC. The patient initially presented with right lower back pain, weight loss, and a loss of appetite. Following systemic immunotherapy with nivolumab and ipilimumab, and right radical nephrectomy, the patient was diagnosed with metastatic clear cell RCC, with new metastatic lesions detected in the liver, and on the chest wall on follow-up imaging. Second-line systemic treatment with pazopanib was initiated. Shortly thereafter, the patient developed severe systemic inflammatory syndrome, resulting in a mental stupor and acute kidney failure. Intensive care, including continuous renal replacement therapy and high-dose immunosuppressants, was administered. The patient\u2019s condition improved significantly with the intensive care regimen, leading to unintended tumor regression. These potentially fatal side effects occurred without infection, as confirmed by negative blood and urine cultures, and were attributed to the recent introduction of pazopanib. Follow-up imaging showed a significant reduction in hepatic metastatic lesions and the disappearance of chest wall nodules. This is the first reported case of RCC tumor regression following the side effects of pazopanib, underscoring the need for further studies into the immune mechanisms involved in RCC treatment and highlighting potential therapeutic strategies that leverage innate immune responses.<\/jats:p>","DOI":"10.3390\/curroncol32050260","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:05:57Z","timestamp":1745989557000},"page":"260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spontaneous Dramatic Regression of Clear Cell Renal Cell Carcinoma After Pazopanib-Induced Severe Systemic Inflammatory Syndrome: A Case Report and Literature Review"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4382-5876","authenticated-orcid":false,"given":"Chi Hyuk","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, 23 Kyung Hee Dae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Jun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, College of Medicine, Kyung Hee University Hospital, 23 Kyung Hee Dae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","first-page":"385","article-title":"Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2020","volume":"55","author":"Kang","year":"2023","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_2","unstructured":"Raman, G., and Tarafdar, S. (2020). Kidney Cancer. Nephrology: A Comprehensive Guide to Renal Medicine, John Wiley & Sons."},{"key":"ref_3","first-page":"400","article-title":"Prediction of cancer incidence and mortality in Korea, 2023","volume":"55","author":"Jung","year":"2023","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma","volume":"4","author":"Flanigan","year":"2003","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.juro.2008.06.030","article-title":"The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses","volume":"180","author":"Shannon","year":"2008","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00000658-195609000-00007","article-title":"Spontaneous regression of cancer: Preliminary report","volume":"144","author":"Everson","year":"1956","journal-title":"Ann. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/02841869009090048","article-title":"The spontaneous regression of cancer: A review of cases from 1900 to 1987","volume":"29","author":"Challis","year":"1990","journal-title":"Acta Oncol."},{"key":"ref_8","first-page":"112","article-title":"Immunology of the Spontaneous Remission of Cancer","volume":"6","author":"Niakan","year":"2019","journal-title":"Int. J. Cancer Clin. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/PPO.0b013e3181867628","article-title":"Contemporary epidemiology of renal cell cancer","volume":"14","author":"Chow","year":"2008","journal-title":"Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-5347(17)73147-3","article-title":"The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy","volume":"20","author":"Bumpus","year":"1928","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/curroncol28050294","article-title":"Spontaneous regression of metastatic renal cell carcinoma after SARS-CoV-2 infection: A report of two cases","volume":"28","author":"Buchler","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40792-020-01103-5","article-title":"Spontaneous regression of breast cancer with immune re-sponse: A case report","volume":"7","author":"Ohara","year":"2021","journal-title":"Surg. Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Roelofsen, T., Wefers, C., Gorris, M.A., Textor, J.C., Massuger, L.F., De Vries, I.J.M., and van Altena, A.M. (2018). Spontaneous regression of ovarian carcinoma after septic peritonitis; a unique case report. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00562"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1758835920915303","DOI":"10.1177\/1758835920915303","article-title":"Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: A systematic review","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000478-200103000-00001","article-title":"Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases","volume":"25","author":"Moch","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_17","unstructured":"Edition, S., Edge, S., and Byrd, D. (2017). AJCC Cancer Staging Manual, Springer."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat. Rev. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2214\/AJR.21.25493","article-title":"Update on the role of imaging in clinical staging and restaging of renal cell carcinoma based on the AJCC 8th edition, from the AJR special series on cancer staging","volume":"217","author":"Elkassem","year":"2021","journal-title":"Am. J. Roentgenol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: The 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H","article-title":"Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2","volume":"80","author":"Bukowski","year":"1997","journal-title":"Cancer: Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Collaborators MRCRC (1999). Interferon-\u03b1 and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet, 353, 14\u201317.","DOI":"10.1016\/S0140-6736(98)03544-2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for ad-vanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3138\/guthrie.50.3.099","article-title":"Efforts to explain spontaneous regression of cancer","volume":"50","author":"Cole","year":"1981","journal-title":"Guthrie J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"Scicluna","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000049008","article-title":"Fever, cancer incidence and spontaneous remissions","volume":"9","author":"Kleef","year":"2001","journal-title":"Neuroimmunomodulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00262-014-1637-5","article-title":"Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma","volume":"64","author":"Ellegaard","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2008.12.010","article-title":"EORTC-GU group expert opinion on metastatic renal cell cancer","volume":"45","author":"Bellmunt","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1752-1947-1-89","article-title":"Spontaneous regression of metastatic renal cell carcinoma: Case report","volume":"1","author":"Lekanidi","year":"2007","journal-title":"J. Med. Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02549723","article-title":"Metastatic renal cell carcinoma (RCC): Spontaneous regression, long-term survival and late recurrence","volume":"23","author":"Goldenberg","year":"1991","journal-title":"Int. Urol. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.clgc.2013.04.006","article-title":"Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial","volume":"11","author":"Hainsworth","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jjco\/hyy053","article-title":"Drug review: Pazopanib","volume":"48","author":"Miyamoto","year":"2018","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2213778","DOI":"10.1080\/0886022X.2023.2213778","article-title":"A case of pazopanib-induced acute kidney injury, reversible hair depigmentation and radiation recall der-matitis","volume":"45","author":"Li","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/1535-7163.MCT-24-0139","article-title":"A senescence-mimicking (senomimetic) VEGFR TKI side effect primes tumor immune responses via IFN\/STING signaling","volume":"23","author":"Dolan","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae Insights: Kidney Cancer, Version 2.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"Motzer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:35Z","timestamp":1760030675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050260"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050260","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}